ORAL PRESENTATIONS OF ORIGINAL RESEARCH WORK AND OF CLINICAL CASES

At the end of this session, participants will be better able to:

• Identify, understand and discuss the nature and results of recent research work done by their peers.

“A Cross-Sectional Study of Factors Associated with Sleep Disturbance in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study”

Marieke Alexandra Neyer

“Use and Perceptions of Nutrition Information Resources Among People with Systemic Sclerosis from the Scleroderma Patient-centered Intervention Network (SPIN)”

Nora Østbø Mork

“Cross-Sectional Study on Factors Associated with Symptoms of Anxiety and Depresssion among People with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study”

Sabrina Provencher

“Seronegative Polyarthritis in Association with Anti-NXP2 Autoantibodies: A Case Series and Literature Review”

Dr. Aurélie Mourot

“Effectiveness and safety of tofacitinib in Canadian patients with rheumatoid arthritis with vs without cardiovascular risk factors: a subgroup analysis of the multicentre, observational CANTORAL study”

Dr. Boulos Haraoui

“An ounce of prevention is worth a pound of cure: Vaccines in Rheumatology”

Dre Ines Colmegna

At the end of this session, participants will be better able to:

• Recognize the importance of rheumatologists in promoting vaccines for immunosuppressed patients with chronic rheumatic diseases.
• Reflect on the value of patient-centered, multimethod, implementation research supported by cross-specialty collaboration.
• Critically analyze the evidence on the safety and effectiveness of COVID-19 vaccines in rheumatic diseases.

“Intérêt de l’éducation thérapeutique du patient dans les maladies rhumatologiques”

Dre Catherine Beauvais

At the end of this session, participants will be better able to:

• Therapeutic Patient Education (TPE): the French recommendations and rheumatology practice.
• Relevance of TPE to security skills of patients treated with biologics.
• Contribution of TPE in self-management of rheumatic diseases.

“Insights from the Hopkins Lupus Cohort”

Dre Michelle Petri

At the end of this session, participants will be better able to:

• Consider multi factorial causality of organ damage in SLE.
• Confront the major burden of non-adherence in SLE.
• Analyse the benefit of therapeutic drug monitoring in SLE.

Moderator: Dr Carol Yeadon

ORAL PRESENTATIONS OF ORIGINAL RESEARCH WORK AND OF CLINICAL CASES

At the end of this session, participants will be better able to:

• Identify, understand and discuss the nature and results of recent research work done by their peers.

“Stressful Life Events in the Year Prior to RA Diagnosis Affect RA Disease Characteristics at Baseline and 1 Year: Results from the Canadian Early Arthritis Cohort (CATCH)”

Nicole Andersen

“Associations among fatigue, vitality, sleep, and health-related quality of life in patients with rheumatoid arthritis: Data from Phase 3 trials of tofacitinib”

Dre Susan Bartlett

“Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis”

Dre Ariane Barbacki

“Patient Preferences for Hydroxychloroquine in Systemic Lupus: Preliminary Analyses”

Dre Celline Brasil

“Scleromyositis is Associated with Distinct Muscle Vasculopathic Features”

Dre Océane Landon-Cardinal

“ADVANCES IN THE PATHOGENESIS OF SPONDYLOARTHRITIS

Dr Robert D Inman

At the end of this session, participants will be better able to:

• Identify gut-joint trafficking in AS
• Demonstrate T cell dysregulation in AS
• Recognize the potential for novel targets in AS

“LA MALADIE DE PAGET EST-ELLE DEVENUE UNE MALADIE OSSEUSE RARE?”

Dr Laëtitia Michou

At the end of this session, participants will be better able to:

• Recognize and discuss the epidemiological variations of Paget’s disease
• Illustrate how the pathophysiology of Paget’s disease can explain these variations
• Explain the clinical implications of the rarefaction of Paget’s disease

“IgG4 RELATED DISEASES”

Dr Hughes Allard-Chamard

At the end of this session, participants will be better able to:

• Define what IS and what is NOT an IgG4 disease
• Briefly establish what we know about the development of IgG4 disease
• Define the rational use of paraclinical tests in IgG4 disease